Muscarinic receptor subtypes on rat pancreatic acini: secretion and binding studies
- PMID: 2426974
- DOI: 10.1152/ajpgi.1986.251.2.G275
Muscarinic receptor subtypes on rat pancreatic acini: secretion and binding studies
Abstract
Characterization of muscarinic receptor subtypes on rat pancreatic acinar cells was examined by using specific muscarinic receptor antagonists to study amylase secretion and binding of [N-methyl-3H]scopolamine ([3H]NMS). Rat pancreatic acini were dispersed in HEPES-Ringer buffer and incubated with acetylcholine +/- 4-diphenylacetoxy-N-methylpiperadine-methiodide (4-DAMP, a specific M2 muscarinic receptor antagonist) or +/- pirenzepine (a specific M1 muscarinic receptor antagonist). 4-DAMP (10(-9) to 10(-6) M) caused a progressive parallel rightward shift in the acetylcholine dose-response curve without a change in maximal amylase release. Only high concentrations of pirenzepine (10(-6) to 10(-4) M) caused a rightward shift in the dose-response curve to acetylcholine. Schild analysis of the data indicated an inhibitory constant (Ki) of 200 pM for 4-DAMP and 183 nM for pirenzepine. The slope of the Schild regression lines was not different from unity, suggesting competitive inhibition. Binding of 50 pM [3H]NMS was specific, rapid, and saturable. [3H]NMS binding was displaced by increasing concentrations of 4-DAMP or pirenzepine with apparent Ki's of 102 pM and 330 nM, respectively, and similar maximal binding levels of 60 fmol/mg prot. We have demonstrated that 4-DAMP has an approximately 1,000-fold greater potency than pirenzepine to inhibit amylase release and binding, indicating that cholinergic-stimulated amylase release from pancreatic acini is mediated by M2 muscarinic receptors.
Similar articles
-
Characterization of muscarinic receptor subtypes on rat pancreatic acini: pharmacological identification by secretory responses and binding studies.Digestion. 1992;52(3-4):194-203. doi: 10.1159/000200953. Digestion. 1992. PMID: 1281128
-
Subtypes of muscarinic receptors in pancreatic exocrine secretion in anesthetized dog.Pancreas. 1989;4(3):339-45. doi: 10.1097/00006676-198906000-00011. Pancreas. 1989. PMID: 2734277
-
A cholinergic antagonist identifies a subclass of muscarinic receptors in isolated rat pancreatic acini.J Pharmacol Exp Ther. 1987 Jan;240(1):118-22. J Pharmacol Exp Ther. 1987. PMID: 2433426
-
[MI cholinergic receptors of gastric secretion: current status].J Pharmacol. 1985;16 Suppl 2:145-69. J Pharmacol. 1985. PMID: 2867250 Review. French.
-
Therapeutic potential of CNS-active M2 antagonists: novel structures and pharmacology.Life Sci. 1993;52(5-6):497-503. doi: 10.1016/0024-3205(93)90307-o. Life Sci. 1993. PMID: 8441330 Review.
Cited by
-
Distribution of nitric oxide synthase and secretory role of exogenous nitric oxide in the isolated rat pancreas.Int J Pancreatol. 2001;29(2):77-84. doi: 10.1385/IJGC:29:2:077. Int J Pancreatol. 2001. PMID: 11876252
-
Multiple roles for cholinergic signaling in pancreatic diseases.World J Gastroenterol. 2022 Jul 7;28(25):2910-2919. doi: 10.3748/wjg.v28.i25.2910. World J Gastroenterol. 2022. PMID: 35978870 Free PMC article. Review.
-
Effect of a new cholinergic agonist, aclatonium napadisilate, on exocrine and endocrine rat pancreas.Dig Dis Sci. 1989 Aug;34(8):1249-56. doi: 10.1007/BF01537274. Dig Dis Sci. 1989. PMID: 2473869
-
Influence of chronic ethanol consumption on the muscarinic cholinergic control of rat pancreatic acinar cells.J Physiol Biochem. 2000 Sep;56(3):145-54. doi: 10.1007/BF03179781. J Physiol Biochem. 2000. PMID: 11198150
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources